ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In the case of CML, more than 35 mutations have been described in the ABL kinase domain from patients with imatinib resistance [55], and in GIST a similar pattern of multiple sites of secondary kinase domain mutations has been seen [54].